BioNTech Investor Day Presentation Deck
High medical need in the adjuvant treatment
of Stage II (high risk)/Stage III colorectal cancer
Stage II
(high risk)
High medical need in the adjuvant treatment of Stage II (high risk)/Stage III colorectal cancer
Colorectal cancer is second deadliest cancer worldwide¹, 5-year OS in regional disease is 71% ²
SoC in Stage II (high risk) and Stage III CRC after removal of the primary tumor and adjuvant chemotherapy is watchful waiting
ctDNA is a marker for minimal residual disease and thus can identify patients at high risk of disease recurrence ³
3,4
In ctDNA-positive, Stage 2 (high risk) and Stage 3 CRC post adjuvant chemotherapy, duration of disease-free survival is 6 months 5
and Stage III Surgery
colorectal
cancer
CT scan
Adjuvant
chemo given
to all patients
CRC, colorectal cancer; ctDNA, circulating tumor DNA; ; OS, overall survival; SoC, standard of care.,
1 WHO factsheet on cancer. 2018; 2 Seer database; 3 Fan G, et al. PLoS One 2017; 12: e0171991;
4 Loupakis F, et al. JCO Precis Oncol 2021; 5:PO.21.00101; 5 Reinert T, et al. JAMA Oncology, 2019; 5:1124-1131.
No residual
disease
Microscopic
residual
disease
NUM
50% Cured by surgery alone
mRNA cancer vaccines
20% Cured by chemo on top of surgery
30% Recur despite surgery + chemo
BIONTECH
101View entire presentation